U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07221214) titled 'GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV' on Oct. 23.
Brief Summary: The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are:
1. Does semaglutide lower the number of alcoholic beverages participants drink alcohol per month?
2. Does semaglutide lower the number of cigarettes participants smoke per month?
3. Does semaglutide decrease the risk for cardiovascular disease among people living with HIV who drink alcohol and/or smoke tobacco?
Researchers will compare the effects of semaglutide to a pla...